So when vaccine skeptic Robert F. Kennedy Jr. was offered the top job at the Department of Health and Human Services, Pfizer ...

The Vyndaqel family of drugs for the treatment of transthyretin amyloid cardiomyopathy is Pfizer’s fourth top-selling product ...

Shares of pharmacy benefit managers extended losses Tuesday after Pfizer Inc. Chief Executive Officer Albert Bourla said ...

Pfizer is fending off investors’ fears about threats to its vaccine business under the Trump administration.

Pfizer said Tuesday it does not expect the Trump administration to make major changes to vaccine policy next year even with ...

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several ...

President-elect was happy that "he and his program [Operation Warp Speed] contributed significantly," to vaccine development, ...

Pfizer said it had achieved $4 billion in net cost savings through 2024 and that it expects full-year 2025 revenue to range ...

Pfizer’s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a "Buy" ...

Shares of Pharmacy-benefit managers (PBMs) including CVS Health Corp (NYSE:CVS), UnitedHealth Group Inc (NYSE:UNH) and Cigna ...

Pfizer Inc. forecast 2025 sales and earnings in line with analysts’ projections, a step toward fending off an activist ...

Revenue in 2025 will be $61 billion to $64 billion, Pfizer said, in line with predictions by Wall Street analysts.